Skip to main content
Skip to main content
ZGNX logo

ZGNX Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

DELISTED

What happened to ZGNX (ZGNX) stock?

ZGNX (ZGNX) no longer trades on public markets. The figures below are historical and are not a current quote.

Vol: 11.25M| 52-wk range: $26.51 – $26.90
Data from FMP · Methodology

For informational purposes only. Not financial advice.

ZGNX — AI-powered stock analysis.

Last analyzed: Sep 4, 2026
Council Score · Weighted Average of 3 Disciplines
Split View 51/100 · B

ZGNX: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Griffin-style lens (simulated)Ken Griffin
Favorable read
Simons-style lens (simulated)Jim Simons
Neutral read
Englander-style lens (simulated)Izzy Englander
Neutral read
Klarman-style lens (simulated)Seth Klarman
Neutral read
Moon AI lens (model)
Neutral read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Weak
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

ZGNX Company Overview

Employees327
Data Provenance | Financial Data Quantitative Analysis

Who Are ZGNX's Competitors?

ZGNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
NVO Novo Nordisk A/S $44.01 -1.23% $195B 925-pillar
VRTX Vertex Pharmaceuticals Incorporated $519.58 -0.29% $132B 965-pillar
REGN Regeneron Pharmaceuticals, Inc. $793.26 -1.78% $81.7B 945-pillar
ARGX argenx SE $984.04 -1.82% $61.2B 975-pillar
UCBJY UCB S.A. $117.06 -1.42% $44.6B 679-signal
ALNY Alnylam Pharmaceuticals, Inc. $247.51 -4.07% $33.1B 895-pillar
RPRX Royalty Pharma plc $58.75 -3.04% $26.0B 725-pillar
INCY Incyte Corporation $123.28 -2.17% $25.0B 985-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are the Key Risks for ZGNX?

Negative return on equity (-82.9%) — the business is not currently generating profit on shareholder capital.

  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Insider selling — insiders were net sellers of roughly $3.3M recently.

Research confidence

Low 12/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price 5 days old
  • No filing on record
  • No analyst coverage

MoonshotScore History

Recorded daily since 2026-08-23 · 4 snapshots

2026-08-23 71
2026-08-24 71
2026-08-25 71
2026-08-26 71

What changed?

The score has stayed at 71.

Over the same 3 days the stock moved +0.0%.

ROE -83%

Key Financial Metrics

Return on equity for ZGNX stands at -82.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.5%, showing how much profit it generates from its asset base. A current ratio of 3.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.9%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

ZGNX operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Emeryville, US. The company is led by CEO Stephen Farr. ZGNX has traded publicly since 2010.

3/8 beats

Earnings Track Record

ZGNX has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1.6% below estimates on average.

Net selling

Insider Activity

The most recent 12 insider filings for ZGNX break down as 12 sales and 0 purchases. On net that is roughly 245K shares disposed (about $3.3M), a signal worth weighing alongside the fundamentals.

ZGNX Financials

Fundamental Snapshot

Return on Equity (TTM)
-82.9%
Current Ratio
3.6

Based on FMP financials and quantitative analysis

ZGNX Latest News

What Investors Ask About ZGNX (ZGNX)

What happened to ZGNX (ZGNX) stock?

ZGNX (ZGNX) no longer trades on public markets. The figures below are historical and are not a current quote.

Can I still buy ZGNX shares?

No. ZGNX stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for ZGNX elsewhere is historical data, not a live market.

Are the figures on this page current?

No. Every number here is the last value recorded before ZGNX stopped trading. Nothing on this page updates, and none of it is a current quote.

Why does this page still exist?

Because people still search for what happened to ZGNX. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

More Stocks We Cover